Skip to main content
Erschienen in: High Blood Pressure & Cardiovascular Prevention 1/2024

08.01.2024 | Original article

Comparison of vitamin K and non-vitamin K oral anticoagulants and the bleeding frequency in the emergency department

verfasst von: Tomo Svaguša, Stjepan Šimić, Filip Grabant, Tatjana Kereš, Ognjen Čančarević, Frane Paić, Danijela Grizelj, Aleksandar Blivajs, Tomislav Bulum, Ingrid Prkačin

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Safety studies of anticoagulant therapy have so far been conducted on many subjects in controlled conditions (i.e., clinically monitored) and demonstrated the noninferiority of new ones over old anticoagulant drugs. Data on the propositions for the presence of symptoms and signs of bleeding among various anticoagulants in the emergency department indicate that these data do not match the data published so far.

Aim

The aim of the study was to investigate the differences in the frequency of bleeding and bleeding-related symptoms as a reason for emergency department attendance in patients on anticoagulant therapy.

Methods

The study included patients from the emergency department of University Hospital for one year, who were on anticoagulant therapy and who met the inclusion criteria. Out of a total of 595 patients, 409 were on warfarin (68.74%), and the rest were taking direct oral anticoagulants (DOAC): dabigatran 71 (11.93%), rivaroxaban 66 (11.09%) and apixaban 49 (8.23%).

Results

Out of 409 patients taking warfarin, 34.4% were adequately anticoagulated with the frequency of bleeding 13.7%, while in 57.2% of patients, PT INR was higher than the reference values with the frequency of bleeding 15.0%. A comparison between all DOAC groups and adequately anticoagulated warfarin patients in the frequency of bleeding and bleeding-related symptoms as a reason for emergency attendance yielded a difference that was marginally statistically significant (Pearson Chi-Square = 7.554, p = 0.052).

Conclusion

Monitoring the frequency of bleeding and bleeding-related symptoms in patients on oral anticoagulant therapy as a reason for emergency department attendance may be a new safety and efficacy factor in real-life patient scenarios.
Literatur
3.
Zurück zum Zitat Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e44S–e88S. https://doi.org/10.1378/chest.11-2292 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e44S–e88S. https://​doi.​org/​10.​1378/​chest.​11-2292
7.
Zurück zum Zitat Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangür H, Daffertshofer M, Edelbusch S, Gröschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Müllges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Röther J, Rossi R, Schäfer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—a national case collection. Int J Stroke. 2017;12:383–91. https://doi.org/10.1177/1747493019895654.CrossRefPubMed Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cangür H, Daffertshofer M, Edelbusch S, Gröschel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, Müllges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, Röther J, Rossi R, Schäfer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—a national case collection. Int J Stroke. 2017;12:383–91. https://​doi.​org/​10.​1177/​1747493019895654​.CrossRefPubMed
12.
Zurück zum Zitat Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–62. https://doi.org/10.1016/S0140-6736(13)62343-0.CrossRefPubMed Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–62. https://​doi.​org/​10.​1016/​S0140-6736(13)62343-0.CrossRefPubMed
14.
Zurück zum Zitat Scharrer S, Primas C, Eichinge S, Tonko S, Kutschera M, Koch R, Blesl A, Reinisch W, Mayer A, Haas T, Austrian IBD Study Group. Inflammatory bowel disease and risk of major bleeding during anticoagulation for venous thromboembolism. Inflamm Bowel Dis. 2021;27:1773–83. https://doi.org/10.1093/ibd/izaa337 Scharrer S, Primas C, Eichinge S, Tonko S, Kutschera M, Koch R, Blesl A, Reinisch W, Mayer A, Haas T, Austrian IBD Study Group. Inflammatory bowel disease and risk of major bleeding during anticoagulation for venous thromboembolism. Inflamm Bowel Dis. 2021;27:1773–83. https://​doi.​org/​10.​1093/​ibd/​izaa337
18.
Zurück zum Zitat Lip GYH, Al-Khatib SM, Cosi FG, Banerjee A, Savelieva I, Ruskin J, Blendea D, Nattel S, De Bono J, Conroy JM, Hess PL, Guasch E, Halperin JL, Kirchhof P, Cosio MDG, Camm AJ. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc. 2014;3: e001179. https://doi.org/10.1161/JAHA.114.001179.CrossRefPubMedPubMedCentral Lip GYH, Al-Khatib SM, Cosi FG, Banerjee A, Savelieva I, Ruskin J, Blendea D, Nattel S, De Bono J, Conroy JM, Hess PL, Guasch E, Halperin JL, Kirchhof P, Cosio MDG, Camm AJ. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc. 2014;3: e001179. https://​doi.​org/​10.​1161/​JAHA.​114.​001179.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, Hu M, Illoh O, Wei Y, Goulding MR, Chillarige Y, Southworth MR, MaCurdy TE, Kelman JA. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132:596–604. https://doi.org/10.1016/j.amjmed.2018.12.023.CrossRefPubMed Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, Hu M, Illoh O, Wei Y, Goulding MR, Chillarige Y, Southworth MR, MaCurdy TE, Kelman JA. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132:596–604. https://​doi.​org/​10.​1016/​j.​amjmed.​2018.​12.​023.CrossRefPubMed
21.
Zurück zum Zitat Steinberg B, Shrader P, Thomas L, Ansell J, Fonarow G, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP, ORBIT-AF Investigators. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes. The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68:2597–604. https://doi.org/10.1016/j.jacc.2016.09.966. Steinberg B, Shrader P, Thomas L, Ansell J, Fonarow G, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP, ORBIT-AF Investigators. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes. The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68:2597–604. https://​doi.​org/​10.​1016/​j.​jacc.​2016.​09.​966.
24.
Zurück zum Zitat Jobski K, Hoffmann F, Herget-Rosenthal S, Dörks M. Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case-control studies. Clin Res Cardiol. 2020;109:465–75. https://doi.org/10.1007/s00392-019-01526-7.CrossRefPubMed Jobski K, Hoffmann F, Herget-Rosenthal S, Dörks M. Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case-control studies. Clin Res Cardiol. 2020;109:465–75. https://​doi.​org/​10.​1007/​s00392-019-01526-7.CrossRefPubMed
25.
Zurück zum Zitat Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Hausler GK, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93https://doi.org/10.1093/eurheartj/ehy136 Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Hausler GK, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93https://​doi.​org/​10.​1093/​eurheartj/​ehy136
26.
Zurück zum Zitat Cerdá M, Cerezo-Manchado JJ, Johansson E, Martínez F, Fernández M, Varela A, Rodríguez S, Bosch F, Santamaría A. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. J Comp Eff Res. 2019;8:165–78. https://doi.org/10.2217/cer-2018-0134.CrossRefPubMed Cerdá M, Cerezo-Manchado JJ, Johansson E, Martínez F, Fernández M, Varela A, Rodríguez S, Bosch F, Santamaría A. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. J Comp Eff Res. 2019;8:165–78. https://​doi.​org/​10.​2217/​cer-2018-0134.CrossRefPubMed
Metadaten
Titel
Comparison of vitamin K and non-vitamin K oral anticoagulants and the bleeding frequency in the emergency department
verfasst von
Tomo Svaguša
Stjepan Šimić
Filip Grabant
Tatjana Kereš
Ognjen Čančarević
Frane Paić
Danijela Grizelj
Aleksandar Blivajs
Tomislav Bulum
Ingrid Prkačin
Publikationsdatum
08.01.2024
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 1/2024
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-023-00616-y

Weitere Artikel der Ausgabe 1/2024

High Blood Pressure & Cardiovascular Prevention 1/2024 Zur Ausgabe

Acknowledgement to Referees

Acknowledgement to Referees

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.